Skip to main content

Unicycive Therapeutics, Inc. (UNCY)

NASDAQ: UNCY · IEX Real-Time Price · USD
2.62 0.06 (2.34%)
Oct 21, 2021 1:46 PM EDT - Market open
Market Cap34.84M
Revenue (ttm)n/a
Net Income (ttm)-2.89M
Shares Out13.30M
EPS (ttm)-0.22
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume40,412
Open2.53
Previous Close2.56
Day's Range2.53 - 2.65
52-Week Range2.39 - 8.73
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 15, 2021

About UNCY

Unicycive Therapeutics is a biotechnology company dedicated to developing treatments for certain medical conditions. Our current development programs are focused on the development of two novel therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for treatment of acute kidney injury (AKI). Renazorb and UNI 494 were initially developed by, and licensed to us from, Spectrum Pharmaceuticals (“Spectrum”) and Sphaera Pharmaceuticals, respectively. Spectrum conducted a Phase 1 clinical tria...

IndustryBiotechnology
IPO DateJul 13, 2021
CEOShalabh Gupta, M.D.
Employees1
Stock ExchangeNASDAQ
Ticker SymbolUNCY
Full Company Profile

Financial Performance

Financial Statements

News

Unicycive Therapeutics to be Added to Russell Microcap® Index

LOS ALTOS, Calif., Sept. 15, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announc...

1 month ago - PRNewsWire

Unicycive Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

LOS ALTOS, Calif., Sept. 7, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announce...

1 month ago - PRNewsWire

Unicycive Therapeutics Announces Second Quarter 2021 Financial Results

LOS ALTOS, Calif., Aug. 16, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today reported...

2 months ago - PRNewsWire

Roth Capital Initiates Coverage On Newly Listed Unicycive

Roth Capital initiated coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a Buy rating and $13.50 price target.  Analyst Elemer Piros says that the Company could submit a marketing application to the...

2 months ago - Benzinga

Unicycive Therapeutics IPO Registration Document (S-1)

Unicycive Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC